{{Rsnum
|rsid=10883421
|Gene=DNMBP
|Chromosome=10
|position=101672341
|Orientation=plus
|GMAF=0.3907
|Assembly=GRCh37
|GenomeBuild=37.1
|dbSNPBuild=131
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 28.6 | 52.4 | 19.0
| HCB | 59.1 | 36.4 | 4.5
| JPT | 64.3 | 28.6 | 7.1
| YRI | 26.2 | 55.7 | 18.0
| ASW | 0.0 | 0.0 | 0.0
| CHB | 59.1 | 36.4 | 4.5
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}[[rs10883421]] is one of 2 SNPs in the [[DNMBP]] gene that has been associated with increased risk for late-onset [[Alzheimer's disease]] in both Japanese and Belgian populations; the other SNP being [[rs3740057]].{{PMID|18359537}}

{{PharmGKB
|RSID=rs10883421
|Name_s=
|Gene_s=DNMBP
|Feature=
|Evidence=PubMed ID:18359537
|Annotation=This variant is associated with Alzheimer dementia in the Belgian population
|Drugs=
|Drug Classes=
|Diseases=Alzheimer Disease
|Curation Level=Curated
|PharmGKB Accession ID=PA161615751
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10883421
|overall_frequency_n=50
|overall_frequency_d=128
|overall_frequency=0.390625
|n_genomes=36
|n_genomes_annotated=0
|n_haplomes=43
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}